Compare · NVO vs SDEV
NVO vs SDEV
Side-by-side comparison of Novo Nordisk A/S (NVO) and Stablecoin Development Corporation (SDEV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SDEV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $208.47B, about 3593.2x SDEV ($58.0M).
- Over the past year, NVO is down 3.6% and SDEV is down 61.5% - NVO leads by 57.9 points.
- SDEV has been more active in the news (6 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for SDEV).
- Company
- Novo Nordisk A/S
- Stablecoin Development Corporation
- Price
- $47.08-8.73%
- $1.15-2.54%
- Market cap
- $208.47B
- $58.0M
- 1M return
- -3.49%
- +11.65%
- 1Y return
- -3.57%
- -61.51%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 4
- 6
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SDEV
- Stablecoin Development Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results
- SEC Form 10-Q filed by Stablecoin Development Corporation
- Amendment: SEC Form SCHEDULE 13D/A filed by Stablecoin Development Corporation
- SEC Form 3 filed by new insider Blynn Henry
- Stablecoin Development Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Executive Officer Kazley Michael John exercised 11,332,020 in-the-money shares at a strike of $0.00 and sold $26,945 worth of shares (24,720 units at $1.09) (SEC Form 4)
- Large owner Framework Ventures Iv L.P. exercised 11,332,020 in-the-money shares at a strike of $0.00 and sold $26,945 worth of shares (24,720 units at $1.09), increasing direct ownership by 100% to 22,668,516 units (SEC Form 4)
- Large owner R01 Fund Lp exercised 11,332,020 in-the-money shares at a strike of $0.00 and sold $26,945 worth of shares (24,720 units at $1.09), increasing direct ownership by 100% to 22,668,516 units (SEC Form 4)
- Stablecoin Development Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits